Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INTACT / MeRCI phase II trial of intratumoral Darleukin and/or Fibromun with Keytruda in anti-PD-1-resistant unresectable melanoma
2024-519326-20-00Phase 2Authorised
- Sponsor
- Philogen
- Start
- Jun 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Immunomodulatory ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 3
01
Overview
Phase 2, randomised, open-label trial of darleukin, onfekafusp alfa and pembrolizumab in melanoma (3 arms), sponsored by Philogen. Primary endpoint: Confirmed objective response rate. Planned start Jun 2026; status: authorised.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on 2024-519326-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-519326-20-00.